Adamantinous craniopharyngioma
MONDO:0002787A craniopharyngioma consisting of broad strands, cords and bridges of a multistratified squamous epithelium with peripheral palisading of nuclei. Diagnostic features include nodules of compact 'wet' keratin and dystrophic calcification. (Adapted from WHO)
Also known as: adamantinomatous craniopharyngioma, adamantinous Rathke's pouch neoplasm, adamantinous Rathke's pouch tumor, adamantinous Rathke's pouch tumour, adamantinous craniopharyngioma (morphologic abnormality), adamantinous neoplasm of Rathke's pouch, adamantinous tumor of Rathke's pouch, adamantinous tumour of Rathke's pouch
1467 clinical trials for this condition and its sub-types, 5 tagged with Adamantinous craniopharyngioma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New drug FOG-001 takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing a new drug, FOG-001, in about 595 people with advanced or metastatic solid tumors, including colorectal, prostate, and liver cancers. The drug is given alone or with other cancer treatments to see if it is safe and shrinks tumors. The study is cu…
Phase 1/2 • Sponsor: Parabilis Medicines, Inc. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Arthritis drug shows promise against rare childhood brain tumor
Disease control Recruiting nowThis study tests a drug called tocilizumab, already used for arthritis, in children and young adults with a rare brain tumor called adamantinomatous craniopharyngioma that has come back or is growing. The goal is to see if the drug can shrink the tumor or stop it from growing. Ab…
Phase 2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for kids with rare brain tumor: targeted pill shows promise
Disease control Recruiting nowThis study tests an oral drug called MEKTOVI (binimetinib) in children and young adults with a rare brain tumor called adamantinomatous craniopharyngioma. The goal is to see if the drug can shrink or control the tumor in patients whose tumor has come back after treatment. About 3…
Phase 2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC